Targets — browse / sort / filter (view)
Data license: CC BY 4.0 · Data source: apt-scout automated curation pipeline (E. Dohi, NCNP) — values harvested from public databases; raw source stored per target
- id
- UniProt accession (human). Links to uniprot.org.
- gene_symbol
- Gene symbol (e.g. ITGB3).
- protein_name
- Protein name (UniProt).
- tier
- Tier 1 = PDB-anchored; Tier 1.5 = AlphaFold-confident.
- has_structure
- 1 if the target protein has a reported experimental 3D structure (PDB). This is the CORE requirement the aptamer-Kd layer is built around — filter to 1 for the structure-backed set.
- evidence_priority
- DETERMINISTIC, reproducible prioritisation (0-1) computed at build time from real harvested columns: 0.35*experimental-structure(PDB=1 / AlphaFold-only=0.3) + 0.30*Open-Targets-top-disease-score + 0.20*PREDICTED-surface-accessibility(A_surface=1) + 0.15*EV-detection(EV-Map). A transparent ranking AID, not a validation; the surface/EV terms are PREDICTIONS/DETECTIONS, not measured EV-surface exposure. Recomputable exactly from this DB.
- has_activation_state_pdb_pair
- 1 if a curated ACTIVE/INACTIVE PDB pair exists (only 11 targets).
- in_cev_map
- Detected in the EV-Map plasma-EV dataset (Rai & Greening 2025, Nat Cell Biol, 10.1038/s41556-025-01795-7) = 3,422 apt-scout targets (broad detected proteome). The EV-Map CONSERVED EV proteome is 182 proteins (42 non-EV); apt-scout matches 104 of these conserved EV-hallmark proteins as targets by gene (the other 78 are not apt-scout targets). Use the ev_hallmark_targets query for that subset. IMPORTANT: EV-Map detection means the protein is EV CARGO (present in the vesicle) — it does NOT mean surface-exposed. Rai & Greening 2025 run a separate membrane-impermeant biotinylation assay giving a 151-protein SURFACEOME, and show the conserved SDCBP/syntenin is luminal (not surface-accessible). For genuine EV-surface accessibility use that 151-protein set, not EV-Map presence.
- has_known_aptamer
- 1 if PubMed '(gene) AND (aptamer OR SELEX)' returned any hit (KEYWORD co-mention, includes false positives — NOT a verified aptamer). For verified aptamers with Kd, see the Binding-affinities (v_kd) layer.
- opentargets_top_disease_score
- Open Targets association score (0-1).
- aptamer_count_pubmed
- Number of PubMed hits for (this protein) AND (aptamer OR SELEX). Keyword co-occurrence — verify each (many co-mention without a real aptamer).
- aptamer_pmids
- The actual PubMed IDs behind the aptamer evidence — click each to read the paper. This is the source of the 'has aptamer' claim.
- surface_class
- PREDICTED membrane topology (HPA-derived, not a measurement): A_surface = integral/ecto cell-surface (predicted EV-surface accessible); A2_pm_peripheral = plasma-membrane cytoplasmic-leaflet (SRC/LYN/RHOA, predicted not reachable); A_assoc = secreted/corona; B_cargo = luminal cargo; unknown = no HPA localization. Lipid asymmetry can partially flip (PS via scramblase); confirm by protease-protection / intact-EV surface labelling. See v_surface_targets.
272 rows where has_cryoEM = 1, in_cev_map = 0 and tier = "Tier 1.5" sorted by evidence_priority descending
This data as json, CSV (advanced)
Suggested facets: pdb_count_total, aptamer_count_pubmed
surface_class 5
- B_cargo 124
- A_surface 112
- A_assoc 20
- A2_pm_peripheral 9
- unknown 7
tier 1
- Tier 1.5 · 272 ✖
in_cev_map 1
- - · 272 ✖
has_structure 1
- 1 272
has_cryoEM 1
- 1 · 272 ✖
has_activation_state_pdb_pair 1
- 0 272
| id | gene_symbol | protein_name | tier | evidence_priority ▲ | has_structure | surface_class | pdb_count_total | alphafold_mean_pLDDT | has_cryoEM | has_activation_state_pdb_pair | activation_state_pdb_active | activation_state_pdb_inactive | has_known_aptamer | aptamer_count_pubmed | aptamer_pmids | in_cev_map | opentargets_top_disease_name | opentargets_top_disease_score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P21439 | ABCB4 | Phosphatidylcholine translocator ABCB4 | Tier 1.5 | 0.806 | 1 | A_surface | 4 | 83.25 | 1 | 0 | 0 | 0 | 0 | progressive familial intrahepatic cholestasis type 3 | 0.851728159166962 | |||
| P31785 | IL2RG | Cytokine receptor common subunit gamma | Tier 1.5 | 0.804 | 1 | A_surface | 14 | 75.5 | 1 | 0 | 1 | 2 | 30800133, 33869115 | 0 | gamma chain deficiency | 0.8469997000418428 | ||
| Q9UM01 | SLC7A7 | Y+L amino acid transporter 1 | Tier 1.5 | 0.804 | 1 | A_surface | 5 | 83.81 | 1 | 0 | 0 | 0 | 0 | lysinuric protein intolerance | 0.8450026270275782 | |||
| P08100 | RHO | Rhodopsin | Tier 1.5 | 0.804 | 1 | A_surface | 4 | 88.75 | 1 | 0 | 1 | 45 | 41963275, 41924874, 41636061, 40808302, 40642289, 40330320, 40045571, 39863313, 39788632, 38070612, 37191882, 36705086, 36696850, 36095194, 36049339, 35622174, 34709779, 34471566, 32696702, 32479610, 32319623, 32119944, 31737572, 31588238, 31535128, 29570714, 29281176, 28648779, 27893356, 25645980, 23757206, 23701883, 25033804, 22689339, 22302221, 22121695, 19766091, 19389625, 16419035, 12123800, 8743323, 7678562, 19188685, 18230760 | 0 | retinitis pigmentosa | 0.8481942240861982 | ||
| P48029 | SLC6A8 | Sodium- and chloride-dependent creatine transporter 1 | Tier 1.5 | 0.804 | 1 | A_surface | 6 | 84.62 | 1 | 0 | 0 | 0 | 0 | creatine transporter deficiency | 0.847268393806457 | |||
| Q9UQD0 | SCN8A | Sodium channel protein type 8 subunit alpha | Tier 1.5 | 0.803 | 1 | A_surface | 4 | 68.38 | 1 | 0 | 0 | 0 | 0 | developmental and epileptic encephalopathy, 13 | 0.8437707419548253 | |||
| O95342 | ABCB11 | Bile salt export pump | Tier 1.5 | 0.801 | 1 | A_surface | 8 | 83.12 | 1 | 0 | 1 | 1 | 36313979 | 0 | progressive familial intrahepatic cholestasis type 2 | 0.8372060401943777 | ||
| P78508 | KCNJ10 | ATP-sensitive inward rectifier potassium channel 10 | Tier 1.5 | 0.801 | 1 | A_surface | 4 | 82.44 | 1 | 0 | 0 | 0 | 0 | EAST syndrome | 0.8357483559927158 | |||
| Q16281 | CNGA3 | Cyclic nucleotide-gated channel alpha-3 | Tier 1.5 | 0.799 | 1 | A_surface | 10 | 74.44 | 1 | 0 | 0 | 0 | 0 | achromatopsia | 0.8315799021867489 | |||
| P13866 | SLC5A1 | Sodium/glucose cotransporter 1 | Tier 1.5 | 0.797 | 1 | A_surface | 4 | 84.38 | 1 | 0 | 0 | 0 | 0 | glucose-galactose malabsorption | 0.8220991027793896 | |||
| Q04844 | CHRNE | Acetylcholine receptor subunit epsilon | Tier 1.5 | 0.797 | 1 | A_surface | 13 | 80.69 | 1 | 0 | 0 | 0 | 0 | Congenital myasthenic syndromes | 0.8223287249629152 | |||
| P23942 | PRPH2 | Peripherin-2 | Tier 1.5 | 0.796 | 1 | A_surface | 1 | 87.0 | 1 | 0 | 0 | 0 | 0 | retinitis pigmentosa | 0.8194208847382956 | |||
| Q9BZV2 | SLC19A3 | Thiamine transporter 2 | Tier 1.5 | 0.796 | 1 | A_surface | 19 | 81.56 | 1 | 0 | 0 | 0 | 0 | biotin-responsive basal ganglia disease | 0.8189646480334981 | |||
| Q5JUK3 | KCNT1 | Potassium channel subfamily T member 1 | Tier 1.5 | 0.795 | 1 | A_surface | 6 | 73.88 | 1 | 0 | 0 | 0 | 0 | developmental and epileptic encephalopathy, 14 | 0.8165232785825526 | |||
| Q9NQW8 | CNGB3 | Cyclic nucleotide-gated channel beta-3 | Tier 1.5 | 0.791 | 1 | A_surface | 9 | 68.12 | 1 | 0 | 0 | 0 | 0 | achromatopsia | 0.8033348000666748 | |||
| Q01718 | MC2R | Adrenocorticotropic hormone receptor | Tier 1.5 | 0.79 | 1 | A_surface | 2 | 85.38 | 1 | 0 | 0 | 0 | 0 | familial glucocorticoid deficiency | 0.8001007686411645 | |||
| O95622 | ADCY5 | Adenylate cyclase type 5 | Tier 1.5 | 0.785 | 1 | A_surface | 2 | 73.19 | 1 | 0 | 0 | 0 | 0 | dyskinesia with orofacial involvement, autosomal dominant | 0.7830401650561951 | |||
| P51168 | SCNN1B | Epithelial sodium channel subunit beta | Tier 1.5 | 0.783 | 1 | A_surface | 5 | 82.44 | 1 | 0 | 0 | 0 | 0 | bronchiectasis with or without elevated sweat chloride 1 | 0.775668400727201 | |||
| O43497 | CACNA1G | Voltage-dependent T-type calcium channel subunit alpha-1G | Tier 1.5 | 0.783 | 1 | A_surface | 2 | 58.22 | 1 | 0 | 0 | 0 | 0 | Spinocerebellar ataxia type 42 | 0.7770459773037601 | |||
| P43004 | SLC1A2 | Excitatory amino acid transporter 2 | Tier 1.5 | 0.783 | 1 | A_surface | 7 | 77.75 | 1 | 0 | 0 | 0 | 0 | developmental and epileptic encephalopathy, 41 | 0.7772658651722512 | |||
| P48547 | KCNC1 | Voltage-gated potassium channel KCNC1 | Tier 1.5 | 0.78 | 1 | A_surface | 10 | 78.56 | 1 | 0 | 0 | 0 | 0 | Progressive myoclonic epilepsy | 0.7675090944252294 | |||
| Q13255 | GRM1 | Metabotropic glutamate receptor 1 | Tier 1.5 | 0.779 | 1 | A_surface | 4 | 70.94 | 1 | 0 | 0 | 0 | 0 | autosomal recessive spinocerebellar ataxia 13 | 0.7631507286490296 | |||
| P51654 | GPC3 | Glypican-3 | Tier 1.5 | 0.779 | 1 | A_surface | 4 | 75.06 | 1 | 0 | 1 | 65 | 42083729, 41790019, 41653459, 41045695, 40825648, 40722645, 39998646, 39874791, 39608318, 39427046, 38910291, 38787447, 38621313, 38368644, 37665421, 36903516, 36457288, 36317566, 36072763, 35788872, 35699181, 35477501, 35051745, 34974867, 34306031, 33254049, 33080969, 32356075, 30347351, 30122918, 29675356, 29605994, 29277631, 27601357, 28263753 | 0 | Simpson-Golabi-Behmel syndrome type 1 | 0.762708583613362 | ||
| P20023 | CR2 | Complement receptor type 2 | Tier 1.5 | 0.776 | 1 | A_surface | 9 | 74.94 | 1 | 0 | 1 | 1 | 33235290 | 0 | immunodeficiency, common variable, 7 | 0.7543125403898414 | ||
| Q86YC3 | NRROS | Transforming growth factor beta activator LRRC33 | Tier 1.5 | 0.773 | 1 | A_surface | 1 | 83.31 | 1 | 0 | 0 | 0 | 0 | seizures, early-onset, with neurodegeneration and brain calcifications | 0.744630610851649 | |||
| O75899 | GABBR2 | Gamma-aminobutyric acid type B receptor subunit 2 | Tier 1.5 | 0.771 | 1 | A_surface | 26 | 77.75 | 1 | 0 | 0 | 0 | 0 | developmental and epileptic encephalopathy, 59 | 0.7356789732167734 | |||
| Q16572 | SLC18A3 | Vesicular acetylcholine transporter | Tier 1.5 | 0.77 | 1 | A_surface | 7 | 76.19 | 1 | 0 | 0 | 0 | 0 | Congenital myasthenic syndromes | 0.7324174860789537 | |||
| P08887 | IL6R | Interleukin-6 receptor subunit alpha | Tier 1.5 | 0.768 | 1 | A_surface | 10 | 77.88 | 1 | 0 | 1 | 18 | 40853309, 38152968, 37034659, 36579647, 35890412, 33590853, 33340765, 32515246, 29211023, 28929152, 26552813, 26383776, 24481022, 24440854, 23235494, 22503683, 22258147, 22094809 | 0 | rheumatoid arthritis | 0.7269057706798291 | ||
| P30542 | ADORA1 | Adenosine receptor A1 | Tier 1.5 | 0.767 | 1 | A_surface | 5 | 92.44 | 1 | 0 | 0 | 0 | 0 | asthma | 0.7232344154541454 | |||
| Q00975 | CACNA1B | Voltage-dependent N-type calcium channel subunit alpha-1B | Tier 1.5 | 0.767 | 1 | A_surface | 7 | 59.91 | 1 | 0 | 1 | 2 | 31118475, 25782368 | 0 | Seizure | 0.7217241968702018 | ||
| Q9Y5Y9 | SCN10A | Sodium channel protein type 10 subunit alpha | Tier 1.5 | 0.764 | 1 | A_surface | 8 | 67.31 | 1 | 0 | 0 | 0 | 0 | atrial fibrillation | 0.7126293968222049 | |||
| Q13705 | ACVR2B | Activin receptor type-2B | Tier 1.5 | 0.763 | 1 | A_surface | 9 | 83.31 | 1 | 0 | 0 | 0 | 0 | Heterotaxia | 0.7109733260300651 | |||
| Q2M385 | MPEG1 | Macrophage-expressed gene 1 protein | Tier 1.5 | 0.761 | 1 | A_surface | 5 | 82.75 | 1 | 0 | 0 | 0 | 0 | immunodeficiency 77 | 0.7043238859467001 | |||
| Q9NPI9 | KCNJ16 | Inward rectifier potassium channel 16 | Tier 1.5 | 0.761 | 1 | A_surface | 4 | 78.12 | 1 | 0 | 0 | 0 | 0 | hypokalemic tubulopathy and deafness | 0.7018965238443493 | |||
| Q9H2X9 | SLC12A5 | Solute carrier family 12 member 5 | Tier 1.5 | 0.76 | 1 | A_surface | 2 | 78.44 | 1 | 0 | 0 | 0 | 0 | genetic developmental and epileptic encephalopathy | 0.6993945840545625 | |||
| Q8IWU4 | SLC30A8 | Proton-coupled zinc antiporter SLC30A8 | Tier 1.5 | 0.759 | 1 | A_surface | 3 | 82.12 | 1 | 0 | 0 | 0 | 0 | type 2 diabetes mellitus | 0.6974093822415375 | |||
| P29371 | TACR3 | Neuromedin-K receptor | Tier 1.5 | 0.758 | 1 | A_surface | 3 | 72.81 | 1 | 0 | 0 | 0 | 0 | hypogonadotropic hypogonadism 11 with or without anosmia | 0.6919271705332203 | |||
| Q86YT5 | SLC13A5 | Na(+)/citrate cotransporter | Tier 1.5 | 0.756 | 1 | A_surface | 4 | 86.06 | 1 | 0 | 0 | 0 | 0 | genetic developmental and epileptic encephalopathy | 0.6853612674939716 | |||
| P03999 | OPN1SW | Short-wave-sensitive opsin 1 | Tier 1.5 | 0.755 | 1 | A_surface | 1 | 86.94 | 1 | 0 | 0 | 0 | 0 | blue color blindness | 0.6823080616118219 | |||
| P15391 | CD19 | B-lymphocyte antigen CD19 | Tier 1.5 | 0.755 | 1 | A_surface | 4 | 62.22 | 1 | 0 | 1 | 13 | 41079126, 40652441, 38661725, 38148412, 36095289, 35829681, 34680368, 34364920, 32401486, 31912987, 29928472, 21127492 | 0 | immunodeficiency, common variable, 3 | 0.6821072538733047 | ||
| P35462 | DRD3 | D(3) dopamine receptor | Tier 1.5 | 0.751 | 1 | A_surface | 6 | 75.38 | 1 | 0 | 0 | 0 | 0 | schizophrenia | 0.6687268941647396 | |||
| Q96RJ3 | TNFRSF13C | Tumor necrosis factor receptor superfamily member 13C | Tier 1.5 | 0.748 | 1 | A_surface | 8 | 63.03 | 1 | 0 | 1 | 1 | 23470998 | 0 | immunodeficiency, common variable, 4 | 0.660711678987284 | ||
| P48764 | SLC9A3 | Sodium/hydrogen exchanger 3 | Tier 1.5 | 0.745 | 1 | A_surface | 1 | 65.94 | 1 | 0 | 0 | 0 | 0 | congenital sodium diarrhea | 0.6503153836708786 | |||
| P11912 | CD79A | B-cell antigen receptor complex-associated protein alpha chain | Tier 1.5 | 0.744 | 1 | A_surface | 5 | 77.06 | 1 | 0 | 0 | 0 | 0 | isolated agammaglobulinemia | 0.6482225796113222 | |||
| Q8NER1 | TRPV1 | Transient receptor potential cation channel subfamily V member 1 | Tier 1.5 | 0.738 | 1 | A_surface | 8 | 71.94 | 1 | 0 | 1 | 2 | 40855286, 28604222 | 0 | migraine disorder | 0.6269329225883602 | ||
| P42658 | DPP6 | A-type potassium channel modulatory protein DPP6 | Tier 1.5 | 0.737 | 1 | A_surface | 8 | 86.69 | 1 | 0 | 1 | 1 | 41313574 | 0 | Autosomal dominant microcephaly | 0.6225938492787458 | ||
| O00591 | GABRP | Gamma-aminobutyric acid receptor subunit pi | Tier 1.5 | 0.736 | 1 | A_surface | 2 | 79.12 | 1 | 0 | 0 | 0 | 0 | migraine disorder | 0.6191855696357259 | |||
| Q01118 | SCN7A | Sodium channel protein type 7 subunit alpha | Tier 1.5 | 0.735 | 1 | A_surface | 2 | 73.75 | 1 | 0 | 0 | 0 | 0 | epilepsy | 0.6174029189677025 | |||
| P28335 | HTR2C | 5-hydroxytryptamine receptor 2C | Tier 1.5 | 0.734 | 1 | A_surface | 8 | 73.56 | 1 | 0 | 0 | 0 | 0 | schizophrenia | 0.6133629296848119 | |||
| P35346 | SSTR5 | Somatostatin receptor type 5 | Tier 1.5 | 0.733 | 1 | A_surface | 7 | 81.25 | 1 | 0 | 0 | 0 | 0 | acromegaly | 0.6094707180356006 |
Advanced export
JSON shape: default, array, newline-delimited
CREATE VIEW v_targets AS
SELECT f.id, n.gene_symbol, n.protein_name, tg.tier,
-- evidence_priority: DETERMINISTIC, reproducible from real DB columns (no LLM).
-- Transparent weights over harvested evidence: structure 0.35, disease importance
-- 0.30 (Open Targets top-disease score), PREDICTED surface accessibility 0.20,
-- EV detection 0.15. A heuristic ranking aid, not a validation; surface/EV terms
-- are predictions/detections, NOT measured EV-surface exposure.
ROUND(
0.35*(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1.0
WHEN CAST(COALESCE(NULLIF(f.alphafold_mean_pLDDT,''),'0') AS REAL)>0 THEN 0.3 ELSE 0.0 END)
+ 0.30*MIN(CAST(COALESCE(NULLIF(f.opentargets_top_disease_score,''),'0') AS REAL), 1.0)
+ 0.20*(CASE sc.surface_class WHEN 'A_surface' THEN 1.0 WHEN 'A_assoc' THEN 0.5 WHEN 'A2_pm_peripheral' THEN 0.2 ELSE 0.0 END)
+ 0.15*(CASE WHEN CAST(COALESCE(f.in_cev_map,0) AS INTEGER)=1 THEN 1.0 ELSE 0.0 END)
, 3) AS evidence_priority,
(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1 ELSE 0 END) AS has_structure,
sc.surface_class,
f.pdb_count_total, f.alphafold_mean_pLDDT, f.has_cryoEM,
f.has_activation_state_pdb_pair, f.activation_state_pdb_active, f.activation_state_pdb_inactive,
f.has_known_aptamer, f.aptamer_count_pubmed, ap.aptamer_pmids,
f.in_cev_map, f.opentargets_top_disease_name, f.opentargets_top_disease_score
FROM v_target_full f
LEFT JOIN target_names n ON n.target_id=f.id
LEFT JOIN targets tg ON tg.id=f.id
LEFT JOIN target_aptamer_pmids ap ON ap.target_id=f.id
LEFT JOIN membrane_surface_class sc ON sc.target_id=f.id;